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Abstract
Background. Cabozantinib is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor 
receptor 2 (VEGFR2) and MET that has demonstrated clinical activity in advanced solid tumors. This open-label, 
phase II trial evaluated cabozantinib in patients with recurrent or refractory glioblastoma (GBM).
Methods. Patients were initially enrolled at a starting dose of 140 mg/day, but the starting dose was amended to 
100 mg/day because of toxicity. Treatment continued until disease progression or unacceptable toxicity. The pri-
mary endpoint was objective response rate assessed by an independent radiology facility using modified Response 
Assessment in Neuro-Oncology criteria. Additional endpoints included duration of response, 6-month and median 
progression-free survival, overall survival, and safety.
Results. Among 152 patients naive to prior antiangiogenic therapy, the objective response rate was 17.6% and 
14.5% in the 140 mg/day and 100 mg/day groups, respectively, which did not meet the predefined statistical target 
for success. The proportions of patients alive and progression free at 6 months were 22.3% and 27.8%, respectively. 
Median progression-free survival was 3.7 months in both groups, and median overall survival was 7.7 months and 
10.4 months, respectively. The incidence of grade 3/4 adverse events (AEs) was 79.4% and 84.7% in the 140 mg/
day and 100 mg/day groups, respectively, and dose reductions due to AEs were experienced by 61.8% and 72.0%, 
respectively. Common grade 3/4 AEs included fatigue, diarrhea, and palmar-plantar erythrodysesthesia syndrome.
Conclusions. Cabozantinib showed evidence of clinical activity in patients with recurrent GBM naive to antiangio-
genic therapy, although the predefined statistical target for success was not met. At the starting doses assessed, 
AEs were frequently managed with dose reductions.
Clinical Trials Registration Number: NCT00704288 (https://www.clinicaltrials.gov/ct2/show/NCT00704288)
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Among primary brain and central nervous system tumors 
diagnosed in the United States between 2006 and 2010, 
glioblastoma (GBM) accounted for 45.6% of malignant 
brain and central nervous system tumors and is the most 
common malignant brain tumor in adults.1 The current 
standard of care for patients with newly diagnosed GBM 
includes surgical resection of the tumor to the extent pos-
sible, followed by adjuvant radiotherapy plus temozo-
lomide2,3; nevertheless, the median 5-year survival rate 
remains less than 5%.1
Treatment options for patients with recurrent dis-
ease are limited and may include repeat surgical resec-
tion, reirradiation, systemic chemotherapy, tumor 
treating fields, bevacizumab, or best supportive care.3 
Bevacizumab monotherapy is approved in the United 
States for patients with recurrent GBM based on a clin-
ically meaningful and durable objective response rate 
(ORR) of 19.6% and a median duration of response 
ranging from 3.9 months to 4.2 months based on World 
Health Organization (WHO) radiographic criteria.3–5 In 
heavily pretreated patients with GBM, the median over-
all survival (OS) with single-agent bevacizumab ranges 
from 7.8 months6 to 9.2 months.7 The Dutch BELOB trial 
in patients with GBM at first recurrence reported 9-month 
OS rates of 38% for bevacizumab, 43% for lomustine, 
59% for bevacizumab/lomustine 90 mg/m2, and 88% for 
bevacizumab/lomustine 110 mg/m2.8 In a phase III trial of 
bevacizumab plus lomustine compared with lomustine 
alone in patients with GBM at first recurrence, median 
progression-free survival (PFS) was 4.2  months ver-
sus 1.5 months and median OS was 9.1 months versus 
8.6 months, respectively.9 GBMs are highly vascularized 
neoplasms, and agents such as bevacizumab that target 
vascular endothelial growth factor (VEGF) have demon-
strated some efficacy in this setting. In addition to the 
VEGF pathway, the MET/hepatocyte growth factor path-
way has been implicated as an important mediator in the 
pathogenesis of GBM.10–13 In particular, MET overexpres-
sion is associated with poor response to treatment and 
shorter survival.12 Furthermore, preclinical data suggest 
that MET overexpression may contribute to bevacizumab 
resistance and that targeting MET may offer a mechan-
ism to prevent or overcome resistance.13,14 The receptor 
tyrosine kinase AXL has also been implicated in GBM 
pathogenesis in preclinical studies and associated with 
a poor prognosis in patients with GBM.15–18 However, 
bevacizumab only inhibits circulating VEGF and has no 
direct effect on the other angiogenic factors or molecular 
targets expressed by the tumor that are known to play a 
role in the pathobiology of GBM. Furthermore, in vitro 
evidence suggests that targeting VEGF alone may drive 
a pro-invasive phenotype.19 As a result, there is a need 
for therapies that target multiple pathways involved in 
GBM pathogenesis and that may overcome mechanisms 
of resistance.
Cabozantinib is an oral tyrosine kinase inhibitor with 
potent activity against MET, VEGF receptors (VEGFRs), 
and AXL.20,21 Preclinical data indicate that cabozantinib 
suppresses MET and VEGFR2 signaling and induces apop-
tosis of endothelial cells and a variety of tumor cell lines. 
For example, cabozantinib significantly improved survival 
in a xenograft mouse model of human GBM.22 In add-
ition, several clinical trials in patients with advanced solid 
tumors have demonstrated that cabozantinib therapy 
can cause tumor regression.23–25 The current phase II trial 
sequentially examined the efficacy and safety of 2 doses 
of cabozantinib in 222 patients with refractory or recur-
rent GBM. Herein we report the results from the subset 
of patients who were naive to antiangiogenic therapy at 
study entry. Results for patients who received prior antian-
giogenic therapy are presented in the companion article 
(Cloughesy et al).
Materials and Methods
Eligibility Requirements
Eligible patients were adults with refractory or recurrent 
GBM in first or second relapse. Patients were required to 
have radiographic evidence of recurrent disease by gad-
olinium-enhanced MRI scan (performed within the past 
14 days and while on a fixed or decreasing dose of gluco-
corticoids for at least 5 days). Some entry criteria differed 
among patients due to amendments to the protocol (see 
Supplementary material). Eligible patients received prior 
temozolomide and radiation therapy (required for patients 
enrolled at the 100 mg/day dose); had a Karnofsky per-
formance status score of ≥60%; and had adequate hemato-
logic, renal, and liver function. Exclusion criteria included 
prior anticancer therapy within 28 days before the first 
dose of cabozantinib (including investigational agents and 
biologic agents) or mitomycin C or nitrosoureas within 42 
Importance of the study
GBM is the most common brain tumor in adults. 
Treatment options are limited for recurrent disease 
and include repeated surgical resection, irradiation, 
chemotherapy, tumor treating fields, or bevaci-
zumab therapy. Despite demonstration of some effi-
cacy with agents that target the VEGF pathway such 
as bevacizumab, the 5-year survival rate for patients 
with GBM remains low, and additional therapies 
are needed. Cabozantinib is an inhibitor of tyrosine 
kinases including VEGFR2, MET, and AXL. The MET 
pathway has been implicated in the pathogenesis of 
GBM and resistance to bevacizumab therapy. In the 
current study, 152 patients with recurrent GBM who 
were naive to prior antiangiogenic therapy were 
treated with cabozantinib at either 140 mg or 100 mg 
orally daily. Cabozantinib showed evidence of clinical 
activity in patients with recurrent GBM naive to prior 
antiangiogenic therapy.
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days before the first dose of cabozantinib, or prior antian-
giogenic therapy (for the group naive to antiangiogenic 
therapy). All patients provided informed written consent. 
The protocol was approved by ethics committees or insti-
tutional review boards at each investigator’s institution. 
This trial was conducted in accordance with the principles 
of the International Conference on Harmonisation (ICH) 
guideline for Good Clinical Practice, the World Medical 
Association Declaration of Helsinki, and Title 21 of the 
United States Code of Federal Regulations.
Study Design and Treatment
This was a phase II, multicenter, open-label, single-agent, 
noncomparator trial that sequentially explored 2 dose lev-
els of cabozantinib in patients with recurrent or refractory 
GBM. Patients were defined to be enrolled upon receipt 
of the first dose of cabozantinib. Patients were initially 
enrolled to oral cabozantinib 140 mg/day (freebase weight); 
however, because rates of dose reduction and interruption 
at 140 mg/day were deemed to be high, a protocol amend-
ment added another cohort (15 antiangiogenic treatment-
naive patients planned) at a reduced starting dose of 100 
mg/day to allow qualitative assessment of the safety of the 
dose. The 100 mg/day starting dose was deemed appro-
priate based on the median average daily dose of the first 
cohort enrolled and initial assessments suggesting con-
tinued efficacy at doses ≤100 mg/day. Another protocol 
amendment added an additional cohort to be enrolled at 
the 100 mg/day starting dose (80 antiangiogenic treatment-
naive patients planned). Treatment was continued until 
documented disease progression or unacceptable toxicity. 
To manage adverse events (AEs), dose could be reduced 
to 100 mg (for those enrolled at 140 mg/day), 60 mg, and 
40 mg; dose could be reduced to lower than 40 mg after 
consultation with the sponsor. Patients naive to antiangio-
genic therapy are the focus of this paper. Further details 
of the study design and amendments to the protocol are 
provided in the Supplementary material.
Efficacy Endpoints and Assessments
The primary endpoint was ORR using criteria of the modi-
fied Response Assessment in Neuro-Oncology (modified 
RANO; Supplementary material) as assessed by an inde-
pendent radiology facility (IRF). For implementation in this 
study, the primary modifications to the RANO criteria for 
time point responses include defining operational con-
ventions for changes in glucocorticoid dose and removal 
of the clinical deterioration component to reduce subject-
ivity and facilitate IRF assessment. Classification of ORR 
required complete response (CR)/partial response (PR) 
confirmed on follow-up imaging at least 4 weeks from ini-
tial response. Secondary endpoints included duration of 
response, 6-month and median PFS, OS, and glucocortic-
oid use. Radiologic evaluations were performed at screen-
ing and generally every 6 to 8 weeks from enrollment until 
disease progression using modified RANO criteria (see 
Supplementary material). Tumor assessments for the pri-
mary efficacy analyses were performed by an IRF to deter-
mine response and/or progression. The minimum lesion 
size required for measurable disease by IRF was 10 mm × 
5 mm, reflecting the implementation of RANO in this study 
before publication of the 10 mm × 10 mm recommended 
criterion for measurable disease.
Safety Assessments
Safety and tolerability assessments included monitor-
ing AEs, performing standard clinical laboratory tests 
(including hematology, serum chemistry, and urinaly-
sis) and physical examinations, and recording electro-
cardiograms. Severity of AEs was assessed by using the 
National Cancer Institute Common Terminology Criteria 
for Adverse Events, version 3.0. Serious AEs were 
defined in accordance with the ICH Guidelines for Clinical 
Safety Data Management: Definitions and Standards for 
Expedited Reporting, Topic E2A.
Statistical Analysis
Results for patients naive to antiangiogenic therapy are 
presented here. Efficacy and safety analyses include all 
such enrolled patients unless otherwise specified. ORR 
was defined as the proportion of patients with measurable 
disease at baseline per modified RANO criteria whose best 
overall response was confirmed CR or confirmed PR. The 
ORR is presented with 2-sided 95% CIs. The planned sam-
ple size to evaluate the primary endpoint was 80 patients to 
evaluate ORR with the following hypotheses (1-sided nom-
inal alpha of 0.025 and power of >90%): H0: ORR = 10% and 
HA: ORR = 25%. The primary endpoint was to be analyzed in 
the last group of patients enrolled at the 100 mg/day dose; 
however, for simplicity, patients naive to antiangiogenic 
therapy at the 100 mg/day dose were retrospectively com-
bined for the analyses presented here. For more details on 
the planned analyses, see Supplementary material.
PFS was calculated as the time from first cabozantinib 
dose to the earlier of documented disease progression per 
modified RANO or death from any cause. OS was calcu-
lated as the time from first cabozantinib dose to death from 
any cause. Efficacy analyses of secondary endpoints for 
duration of response, PFS, and OS used the Kaplan–Meier 
method. All statistical analysis was performed using SAS 
version 8.2 or higher.
Results
Patients
A total of 222 patients were enrolled between June 2008 
and June 2012; at study entry, 152 of 222 patients (68%) 
were naive to prior antiangiogenic therapy and are the 
subject of this report. After the first 34 naive patients were 
enrolled and received at least 1 dose of cabozantinib at 
140 mg/day, the dose was reduced to 100 mg/day and an 
additional 118 naive patients were treated at the 100 mg/
day dose. Among patients naive to prior antiangiogenic 
therapy, baseline demographics and clinical characteris-
tics were similar between the 2 cabozantinib dose groups 
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(Table 1). The majority of patients were white males. 
Approximately one third of patients received >1 prior sys-
temic therapy before study entry.
Response to Treatment
Among the 152 patients naive to prior antiangiogenic ther-
apy, 151 had measurable disease at baseline by the IRF 
and were included in the response assessment (Table 2). 
Subgroup analysis by cabozantinib starting dose demon-
strated an ORR of 17.6% (95% CI, 6.8%–34.5%) in patients 
who received 140 mg/day and 14.5% (95% CI, 8.7%–22.2%) 
in those who received 100 mg/day. The results for ORR did 
not meet the predefined statistical target for success. The 
median duration of ORR was 5.9 months (range, 1.9–12.8 
mo) in the 140 mg/day group and 8.5 months (range, 1.0–
9.3 mo) in the 100 mg/day group. Overall, 90% of patients 
with measurable disease at baseline and ≥1 evaluable 
postbaseline assessment had a detectable decrease in 
tumor volume (Fig. 1). The median follow-up for scans was 
3.6 months (range, 0.03–25.0) in the 140 mg/day group and 
3.6 months (range, 0.03–17.5) in the 100 mg/day group.
Key Secondary Efficacy Endpoints
The median PFS was 3.7 months in both the 140 mg/day 
and 100 mg/day dose groups (Fig. 2A). The Kaplan–Meier 
estimates of the proportion of patients alive and pro-
gression free at 6 months were 22.3% in the 140 mg/day 
group and 27.8% in the 100 mg/day group. The estimated 
median OS was 7.7 months in the 140 mg/day group and 
10.4  months in the 100  mg/day group (Fig.  2B). Overall, 
100 of 152 patients (66%) subsequently received salvage 
therapy with bevacizumab. Among patients who reported 
glucocorticoid use at baseline (n = 70), there was a trend 
for them to receive stable or decreasing glucocorticoid 
doses over time (Fig. 3).
Safety and Tolerability
The median duration of treatment was 14.8 weeks (range, 
0.3–108.4  wk) in the 140  mg/day group and 15.1 weeks 
(range, 0.7–79.0 wk) in the 100 mg/day group. All patients 
received ≥1 dose of cabozantinib and reported ≥1 treat-
ment-emergent adverse event (TEAE); those occurring in 
≥15% of patients (all grades) are summarized in Table  3. 
The most common TEAEs included fatigue (76.3%), diar-
rhea (62.5%), decreased appetite (47.4%), palmar-plantar 
erythrodysesthesia syndrome (39.5%), nausea (38.8%), 
Table 1 Baseline demographics and clinical characteristics of the 
patients
Characteristic Patients, n (%)
140 mg/day 
(n = 34)
100 mg/day
(n = 118)
Age, y
 Median (range) 55 (20–73) 56.5 (21–82)
Sex
 Male 24 (70.6) 72 (61.0)
 Female 10 (29.4) 46 (39.0)
Race
 White 29 (85.3) 104 (88.1)
 Black 3 (8.8) 5 (4.2)
 Asian 1 (2.9) 4 (3.4)
 Native American 0 2 (1.7)
 Other 1 (2.9) 4 (3.4)
Karnofsky performance status
 90–100 22 (64.7) 74 (62.7)
 70–80 11 (32.4) 44 (37.3)
 ≤60 1 (2.9) 0
Years since initial diagnosis
 Median (range) 0.95 (0.1–5.3) 0.94 (0.3–16.7)
GBM type
 Primary 29 (85.3) 100 (84.7)
 Secondary 5 (14.7) 18 (15.3)
Prior radiotherapy for GBM
 Yes 30 (88.2) 117 (99.2)
 No 4 (11.8) 1 (0.8)
Prior lines of systemic therapy for GBM
 0 3 (8.8) 0
 1 18 (52.9) 77 (65.3)
 2 12 (35.3) 39 (33.1)
 ≥3 1 (2.9) 2 (1.7)
Steroid use at baseline*
 Yes 14 (41.2) 56 (47.5)
 No/unknown 20 (58.8) 62 (52.5)
*Received at least 7 days of systemic steroids within 30 days before 
the first dose of cabozantinib.
Table 2 Best overall response to treatment by modified RANO  
criteria (per IRF)
Patients, n (%)
140 mg/day  
(n = 34)
100 mg/day 
(n = 117)*
Objective response rate 6 (17.6) 17 (14.5)
Best overall response
 Confirmed partial response 6 (17.6) 17 (14.5)
 Stable disease 20 (58.8) 79 (67.5)
 Progressive disease 4 (11.8) 14 (12.0)
 Unevaluable or missing** 4 (11.8) 7 (6.0)
Duration of objective response, mo
 Median (range) 5.9 (1.9–12.8) 8.5 (1.0–9.3)
*One patient lacked measurable disease at baseline and is not 
included.
**Unevaluable by modified RANO or no postbaseline tumor 
assessments.
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headache (36.8%), constipation (34.2%), hypertension 
(32.2%), weight decrease (31.6%), and dysphonia (30.9%).
Adverse events were generally manageable with dose 
reductions or dose interruptions. Dose reductions due to 
an AE were required in 21 (61.8%) patients in the 140 mg/
day group and 85 (72.0%) in the 100  mg/day group. 
Adverse events were reported as the primary reason for a 
dose interruption in 20 (58.8%) patients in the 140 mg/day 
group and 73 (61.9%) patients in the 100  mg/day group. 
The median average daily dose was 111.1 mg/day (range, 
28.4–140 mg/day) in the 140 mg/day group and 71.5 mg/
day (range, 25.1–100  mg/day) in the 100  mg/day group. 
Adverse events resulted in treatment discontinuation in 6 
(17.6%) patients in the 140 mg/day group and 22 (18.6%) 
patients in the 100 mg/day group.
Serious AEs were reported in 18 (52.9%) patients in the 
140 mg/day group and 61 (51.7%) patients in the 100 mg/
day group and were similar in the 2 dose groups. In the 
overall population, serious AEs that occurred at a fre-
quency >2% were convulsion (9.9%), deep vein thrombosis 
(5.3%), hemiparesis (4.6%), dehydration (3.9%), intracranial 
hemorrhage (2.6%), confusional state (2.6%), and vomiting 
(2.6%). One hundred twenty-two deaths were reported: 
31 (91.2%) in the 140 mg/day group and 91 (77.1%) in the 
100 mg/day group. Grade 5 AEs were reported in 8 (6.8%) 
patients in the 100 mg/day group and no patients in the 
140  mg/day group. Grade 5 AEs consisted of pulmonary 
embolism (in 2 patients) and intracranial hemorrhage, 
acute respiratory failure, cardiac arrest, death, disease pro-
gression, and gastrointestinal ulcer hemorrhage (1 patient 
each). Four of these grade 5 AEs (2 pulmonary embolisms, 
1 gastrointestinal ulcer hemorrhage, and 1 death) were 
assessed as treatment related.
Discussion
Patients with recurrent GBM have limited treatment 
options. Despite not meeting the predefined statistical 
target for success, results from this phase II trial suggest 
that cabozantinib has clinical activity in patients who have 
not received prior antiangiogenic therapy. Comparison of 
ORR with cabozantinib (15.2%) across both dosing cohorts 
with bevacizumab monotherapy is difficult as the studies 
evaluating these agents employed different response cri-
teria (Macdonald vs modified RANO). The trial did not have 
a comparator arm, and interpretations based on cross-
trial comparisons are difficult due to differences in patient 
populations, assessments, and study design. Nonetheless, 
the results for PFS and OS with cabozantinib compare well 
with those reported for other therapies. The median PFS of 
3.7 months in both cabozantinib groups is similar to that 
of monotherapy with bevacizumab (4.2 mo),7 cediranib 
(3.1 mo),26 and axitinib (3.0 mo)27 in patients with recurrent 
GBM. The median OS of 10.4 months in the cabozantinib 
100 mg/day group is also similar to results observed with 
bevacizumab (median OS, 9.2 mo). Although the effect of 
salvage bevacizumab therapy on survival in the current 
study is unknown, it may not be inconsequential.7 In add-
ition, most patients receiving cabozantinib did not experi-
ence a change in the pattern of tumor progression (most 
Fig. 1 Best tumor size change from baseline in target lesion per IRF using modified RANO criteria in patients who had measurable disease at 
baseline and ≥1 evaluable postbaseline radiographic scan. Lines indicate the threshold for response and progression per RANO criteria, ≥50% 
decrease and ≥25% increase, respectively. Partial responses were confirmed in 6 patients in the 140 mg/day group and 17 in the 100 mg/day 
group. *Confirmed partial response.
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Fig. 2 Kaplan–Meier estimates of (A) progression-free survival and (B) overall survival by dose group.
Fig. 3 Average daily glucocorticoid dose up to last treatment date among patients who reported any glucocorticoid use at baseline.
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Table 3 Treatment-emergent adverse events (TEAEs) reported in ≥15% of patients
Adverse Event* Patients, n (%)
140 mg/day (n = 34) 100 mg/day (n = 118)
All Grades Grade 3/4 All Grades Grade 3/4
Any TEAE 34 (100) 27 (79.4) 118 (100) 100 (84.7)
Fatigue 27 (79.4) 13 (38.2) 89 (75.4) 22 (18.6)
Diarrhea 23 (67.6) 2 (5.9) 72 (61.0) 8 (6.8)
Decreased appetite 18 (52.9) 1 (2.9) 54 (45.8) 5 (4.2)
PPES 14 (41.2) 3 (8.8) 46 (39.0) 11 (9.3)
Nausea 12 (35.3) 2 (5.9) 47 (39.8) 3 (2.5)
Headache 16 (47.1) 5 (14.7) 40 (33.9) 7 (5.9)
Constipation 17 (50.0) 0 35 (29.7) 0
Hypertension 12 (35.3) 1 (2.9) 37 (31.4) 9 (7.6)
Weight decreased 9 (26.5) 0 39 (33.1) 7 (5.9)
Dysphonia 13 (38.2) 0 34 (28.8) 0
AST increased 11 (32.4) 1 (2.9) 35 (29.7) 3 (2.5)
ALT increased 11 (32.4) 3 (8.8) 33 (28.0) 10 (8.5)
Convulsion 12 (35.3) 3 (8.8) 29 (24.6) 12 (10.2)
LDH increased 8 (23.5) 0 33 (28.0) 3 (2.5)
Hypophosphatemia 6 (17.6) 3 (8.8) 35 (29.7) 17 (14.4)
Confusional state 8 (23.5) 4 (11.8) 31 (26.3) 2 (1.7)
Stomatitis 13 (38.2) 1 (2.9) 26 (22.0) 3 (2.5)
Vomiting 10 (29.4) 1 (2.9) 25 (21.2) 4 (3.4)
Abdominal pain 10 (29.4) 1 (2.9) 24 (20.3) 3 (2.5)
Thrombocytopenia 1 (2.9) 0 33 (28.0) 8 (6.8)
Pain in extremity 8 (23.5) 0 25 (21.2) 2 (1.7)
Insomnia 11 (32.4) 0 21 (17.8) 0
Gait disturbance 9 (26.5) 2 (5.9) 23 (19.5) 7 (5.9)
Hair color changes 8 (23.5) 0 23 (19.5) 0
Leukopenia 1 (2.9) 1 (2.9) 30 (25.4) 11 (9.3)
Lipase increased 4 (11.8) 3 (8.8) 26 (22.0) 12 (10.2)
Cough 7 (20.6) 0 21 (17.8) 0
Dysgeusia 6 (17.6) 0 22 (18.6) 0
Anxiety 6 (17.6) 0 21 (17.8) 0
Oral pain 4 (11.8) 2 (5.9) 23 (19.5) 3 (2.5)
Depression 4 (11.8) 0 22 (18.6) 1 (0.8)
Dry skin 12 (35.3) 0 14 (11.9) 0
Hemiparesis 3 (8.8) 0 23 (19.5) 10 (8.5)
Dyspepsia 5 (14.7) 0 20 (16.9) 0
Edema peripheral 4 (11.8) 0 21 (17.8) 0
Oropharyngeal pain 9 (26.5) 0 16 (13.6) 0
Rash 6 (17.6) 0 19 (16.1) 1 (0.8)
Hypokalemia 5 (14.7) 1 (2.9) 19 (16.1) 7 (5.9)
Neutropenia 5 (14.7) 2 (5.9) 19 (16.1) 5 (4.2)
Dyspnea 4 (11.8) 0 18 (15.3) 1 (0.8)
Dizziness 10 (29.4) 1 (2.9) 11 (9.3) 0
Cognitive disorder 7 (20.6) 1 (2.9) 13 (11.0) 1 (0.8)
Lymphopenia 7 (20.6) 3 (8.8) 13 (11.0) 4 (3.4)
Proteinuria 8 (23.5) 0 12 (10.2) 1 (0.8)
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had a local pattern of progression at baseline) and experi-
enced a decrease in glucocorticoid usage over time.
This was the first study of cabozantinib in patients with 
GBM, and changes were made to the study design, end-
points, and assessments during the trial. The decision to 
analyze patients by prior treatment with antiangiogenic 
therapy was based on initial data that showed efficacy 
differences between these populations. Assessment of 
response using modified RANO was introduced later in 
the study; however, all groups were analyzed using the 
same modified RANO criteria. In addition, groups were 
retrospectively combined for determination of ORR for 
simplicity of the data presentation, increasing the size of 
the analysis group used for ORR beyond the planned size. 
Some differences in entry criteria and the schedule of 
tumor assessments also existed between these groups. 
Nonetheless, this study provides an initial assessment of 
the activity of cabozantinib in patients with GBM.
The patient population in the cabozantinib trial is typ-
ical of patients with recurrent disease in that most had 
received standard first-line therapy for GBM (ie, surgery 
and radiotherapy plus temozolomide). In addition, many of 
the patients received high doses of corticosteroids for pro-
longed periods of time. A high incidence of comorbidities 
that may be attributable to either advanced GBM or prior 
therapy was observed. Overall, the reported AEs were con-
sistent with the known safety profile of cabozantinib23,28 
and are consistent with AEs typically associated with this 
class of agents. The overall incidence of AEs was not lower 
at the 100  mg/day dose compared with the 140  mg/day 
dose, and dose reductions or interruptions were frequently 
used to manage AEs in both dose groups. Efficacy results 
were similar in the 2 dose groups, and additional studies 
might determine if efficacy could be maintained and tol-
erability improved with a lower starting dose. A  lower 
dose of 60 mg/day has been approved for the treatment 
of advanced renal cell carcinoma, whereas the 140 mg/day 
dose has been approved for treatment of medullary thyroid 
cancer, based on results from the pivotal phase III trials.23,28
Although the predefined statistical target for success 
was not met, cabozantinib showed evidence of clinical 
activity in patients with refractory or recurrent GBM who 
had not received prior antiangiogenic therapy. Further 
assessment of activity and tolerability at a lower starting 
dose would be necessary to better evaluate cabozantinib in 
this patient population.
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